Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ROS1 positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TPX-0005 Sensitive: B - Late Trials IASLC-TTLC 2023 - 5 days (New C3) TPX-0005 Sensitive : B IASLC-TTLC 2023 - 5d	TPX-0005 Sensitive: B - Late Trials IASLC-TTLC 2023 - 5 days TPX-0005 Sensitive : B IASLC-TTLC 2023 - 5 days - (New C3)
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 positive	Lung Cancer	ROS1 positive	Lung Cancer	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2
ROS1 positive	Mesothelioma	ROS1 positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TQ-B3139 Sensitive: C3 – Early Trials TQ-B3139 Sensitive : C3	TQ-B3139 Sensitive: C3 – Early Trials TQ-B3139 Sensitive : C3
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	TPX-0005 Sensitive: C3 – Early Trials TPX-0005 Sensitive : C3	TPX-0005 Sensitive: C3 – Early Trials TPX-0005 Sensitive : C3
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ROS1 inhibitor Sensitive: C3 – Early Trials ROS1 inhibitor Sensitive : C3	ROS1 inhibitor Sensitive: C3 – Early Trials ROS1 inhibitor Sensitive : C3